<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085668</url>
  </required_header>
  <id_info>
    <org_study_id>RE-ADAPT-HF</org_study_id>
    <secondary_id>CIV-13-10-011660</secondary_id>
    <nct_id>NCT02085668</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Patients With Chronic Heart Failure</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Open-label, Feasibility, Safety and Efficacy Study of Renal Denervation in Patients With Chronic Heart Failure (CHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to investigate the safety and effectiveness of renal denervation&#xD;
      for the treatment of chronic heart failure (CHF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a major public health problem. It is associated with high mortality,&#xD;
      frequent hospitalization and represents a large cost to the health care system. Therapies to&#xD;
      ameliorate the high mortality and morbidity of heart failure have focused on abrogation of&#xD;
      activated neurohormonal systems associated with this condition. These systems include the&#xD;
      renin-angiotensin-aldosterone system and the sympathetic nervous system.&#xD;
&#xD;
      Strategies to ameliorate sympathetic activation have primarily focused on blockade of the&#xD;
      beta-adrenoceptors that mediate the adverse effects of activation of this system upon the&#xD;
      myocardium. This has been a highly successful strategy with beta-blockers resulting in an&#xD;
      approximately 35% reduction in mortality as well as improvements in hospitalization and&#xD;
      quality of life and attenuation of disease progression.&#xD;
&#xD;
      However, less than full blockade of the effects of the sympathetic nervous system is achieved&#xD;
      with the use of conventional doses of beta-blockers. Moreover, a not insignificant fraction&#xD;
      of patients are unable to tolerate beta-blockers or are not able to have them up-titrated to&#xD;
      target effective doses, in large part because of the systemic nature of these agents, whereas&#xD;
      renal denervation allows the selective removal of the kidney's contribution to central&#xD;
      sympathetic drive without blunting other compensatory mechanisms.&#xD;
&#xD;
      The renin-angiotensin-aldosterone axis has also been found to be a key system involved in&#xD;
      heart failure disease progression and it too may be inhibited by renal sympathetic&#xD;
      denervation.&#xD;
&#xD;
      Therefore, a clear need exists for further strategies to beneficially manipulate the&#xD;
      sympathetic activation that is characteristic of the heart failure disease process.&#xD;
&#xD;
      Cardiorenal syndrome is a major comorbid condition of patients with advanced chronic heart&#xD;
      failure. In the setting of renal hypoperfusion and/or activation of neurohormonal and&#xD;
      cytokine systems there is a reduction in glomerulofiltration. Renal function has been found&#xD;
      to be a major determine of prognosis in these patients. Strategies to ameliorate cardiorenal&#xD;
      syndrome are being actively pursued. There is considerable a priori evidence to suggest that&#xD;
      the sympathetic nervous system, in particular renal sympathetic, is a key factor to the&#xD;
      progression of cardiorenal syndrome and impaired tubulo-glomerular feedback. In particular&#xD;
      renal sympathetics reduce renal perfusion through vascular alpha adrenergic receptor&#xD;
      stimulation as well as, indirectly, through stimulation of local release of adenosine causing&#xD;
      afferent glomerular arteriole constriction. We hypothesize that by disrupting renal&#xD;
      sympathetic afferent and efferent activity these salutary adenosine inhibitory mediated&#xD;
      effects will be demonstrated using the renal denervation approach.&#xD;
&#xD;
      A number of studies with hypertension patients indicate that the Symplicity Catheter System&#xD;
      can safely denervate the kidney without significant periprocedural complications.&#xD;
&#xD;
      In a small first-in man pilot study, involving seven normotensive patients with chronic heart&#xD;
      failure, six months after renal denervation their 6-min walk distance improved significantly&#xD;
      and the patients' self-assessment of well-being also improved. No procedural or post&#xD;
      procedural complications following renal denervation in patients in 6 months of intensive&#xD;
      follow-up were found.&#xD;
&#xD;
      The investigators believe that therapeutic renal denervation using the Symplicity Catheter is&#xD;
      a promising therapy for patients with elevated sympathetic activity, as in CHF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of renal denervation with the Symplicity Catheter System with special consideration of clinically significant periprocedural adverse events in CHF patients</measure>
    <time_frame>Baseline visit for treatment group, month 6 visit for control group</time_frame>
    <description>Number of complications associated with the delivery and/or use of the Symplicity Catheter (e.g., vascular injury and bleeding complications, access site hematoma, etc.).&#xD;
Vital signs, blood and urine measurements taken before, during and after the denervation procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologic response to renal denervation: ventricular function</measure>
    <time_frame>From denervation prodecure to 6 months after renal denervation procedure</time_frame>
    <description>Measured by echocardiography at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic Response to renal denervation: renal function</measure>
    <time_frame>From denervation prodecure to 6 months after renal denervation procedure</time_frame>
    <description>Calculated by glomerular filtration rate (GFR) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic Response to renal denervation: symptomatology/Quality of Life</measure>
    <time_frame>From denervation prodecure to 6 months after renal denervation procedure</time_frame>
    <description>Measured by EuroQol - 5 dimensions (EQ-5D) and by Kansas City Cardiomyopathy questionnaires at 6 months after renal denervation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic Response to renal denervation: additional parameters</measure>
    <time_frame>From denervation prodecure to 6 months after renal denervation procedure</time_frame>
    <description>Composite measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Cardio-Renal Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation and maintenance of heart failure medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation (Symplicity™)</intervention_name>
    <description>Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Renal denervation with Symplicity™ Renal Denervation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association Class II-III symptoms of chronic heart failure&#xD;
&#xD;
          -  Systolic left ventricular dysfunction as assessed by echocardiogram with left&#xD;
             ventricular ejection fraction in a range of 10%- 40%.&#xD;
&#xD;
          -  GFR &gt;30 mL/min/1.73m2&#xD;
&#xD;
          -  Brain natriuretic Peptide (BNP) &gt;100 pg/ml or N terminal (NT)-Pro-BNP &gt;400 pg/ml.&#xD;
&#xD;
          -  Optimal medical therapy according to current guidelines for CHF management. Treatment&#xD;
             for HF must be stable (including drug and dose) for at least 4 weeks prior to&#xD;
             procedure, with the exception of diuretics, where stability is required for at least 2&#xD;
             weeks.&#xD;
&#xD;
          -  others&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal arterial anatomy that is ineligible for treatment&#xD;
&#xD;
          -  CHF caused by pericarditis or by acute myocarditis or by endocrine diseases.&#xD;
&#xD;
          -  Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within&#xD;
             three 12 weeks of the screening visit.&#xD;
&#xD;
          -  Office systolic BP at screening less than 90 mmHg&#xD;
&#xD;
          -  Primary pulmonary hypertension.&#xD;
&#xD;
          -  Clinically significant cardiac structural valvular disease, unless corrected by a&#xD;
             properly functional prosthetic valve&#xD;
&#xD;
          -  Major surgery, including bariatric surgery, in the previous 12 weeks before baseline.&#xD;
&#xD;
          -  Contrast media administration in the previous 30 days before baseline.&#xD;
&#xD;
          -  Known hypersensitivity to material of the Symplicity Catheter.&#xD;
&#xD;
          -  Inpatient hospitalization for decompensated HF in the previous 60 days before&#xD;
             baseline.&#xD;
&#xD;
          -  others&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Böhm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix Mahfoud, MD</last_name>
    <phone>+49 6841 16 21346</phone>
    <email>felix.mahfoud@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian D Ukena, MD</last_name>
    <phone>+49 6841 16 21346</phone>
    <email>christian.ukena@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Paracelsus Medical University</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <investigator>
      <last_name>Uta C Hoppe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathias Brandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Beschorner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Institute Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eckart Fleck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Kelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katja Twelker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gießen Marburg</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Holger Nef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Dörr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Erwin Blessing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Müller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Saarland</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Michael Böhm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Mahfoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig, Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Philipp Lurz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Müller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Axel Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Geisler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <investigator>
      <last_name>Bert Andersson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bengt Rundqvist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thomas Lüscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabella Sudano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Cardio-Renal Syndrome</keyword>
  <keyword>Renal Denervation</keyword>
  <keyword>Symplicity</keyword>
  <keyword>Sympathetic activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

